The stock's sharp rise during regular market hours on January 16 stemmed from traders reacting to CEO Lisa Conte's virtual presentation at the Lytham Partners Healthcare Investor Summit the prior day, where she outlined near-term catalysts including a recently announced U.S. licensing agreement for crofelemer products. This deal, revealed on January 12, provides up to $38 million—$18 million upfront plus milestones—from Future Pak for exclusive rights to Mytesi (for HIV-related diarrhea) and Canalevia (for veterinary use), freeing resources for Jaguar's rare-disease pipeline. High premarket volume (over 11 million shares, exceeding the 2.1 million float) and retail buzz on social platforms amplified the move, with the microcap structure fueling rapid gains amid positive sentiment on funding stability from recent 8-K filings.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.